https://allsci.com/news/licensing-and-partnerships/onvansertib-license-dispute-cardiff-and-nerviano/ AllScien 2026-09-14T17:19:24.459842Z Cardiff and Nerviano settle onvansertib license dispute ahead of planned Phase III trial https://allsci.com/news/clinical-trials/gensci148-phase-i-trial-registers-for-four-target/ AllScien 2026-09-14T17:09:07.083010Z GenSci registers Phase I trial of four-target retinal fusion protein across three indications https://allsci.com/news/clinical-trials/lpcn-1154-lipocine-starts-second-phase-iii-for/ AllScien 2026-09-14T16:57:20.630010Z Lipocine starts second Phase III for postpartum depression drug after first trial misses endpoint https://allsci.com/news/clinical-trials/alv-100-trial-alveus-launches-phase-ii-preserve/ AllScien 2026-09-14T16:48:40.885766Z Alveus takes aim at post-semaglutide weight regain with ALV-100 https://allsci.com/news/clinical-trials/yy003-phase-ii-revelyxs-clears-hurdle-potential/ AllScien 2026-09-14T15:27:29.206832Z Revelyx reports positive Phase II data for recombinant liquid botulinum toxin https://allsci.com/news/clinical-trials/sab01-clinical-trial-santa-ana-bio-advances/ AllScien 2026-09-14T15:17:20.372731Z Santa Ana Bio takes KIT/Siglec-6 bispecific SAB01 into first-in-human testing https://allsci.com/news/approvals/walvax-mrna-vaccine-china-approves-walvaxs-third/ AllScien 2026-09-14T14:38:05.592234Z China approves Walvax’s third mRNA COVID-19 vaccine, targeting the Omicron JN.1 strain https://allsci.com/news/clinical-trials/risvutatug-rezetecan-cuts-death-risk-54-versus/ AllScien 2026-09-14T13:37:31.112147Z Hansoh/GSK’s risvutatug rezetecan delivers 54% OS risk reduction in relapsed SCLC https://allsci.com/news/clinical-trials/mri-surveillance-sclc-phase-iii-maverick-trial/ AllScien 2026-09-14T13:12:36.033336Z MAVERICK Phase III data support MRI surveillance alone in SCLC https://allsci.com/news/clinical-trials/rybrevant-egfr-exon-20-rybrevants/ AllScien 2026-09-14T12:48:46.484350Z J&J's Rybrevant shows numerical OS gain in PAPILLON, but final analysis misses significance https://allsci.com/news/approvals/joenja-approval-fda-approves-for-children-aged-4/ AllScien 2026-09-14T12:10:17.958370Z Pharming expands Joenja's US indication to children aged 4–11 with APDS https://allsci.com/news/approvals/isembyld-fda-approval-approves-scholar-rocks-as/ AllScien 2026-09-14T11:52:00.103519Z US FDA approves Scholar Rock’s Isembyld as first muscle-targeted SMA therapy https://allsci.com/news/clinical-trials/her2-mutant-lung-cancer-enhertu-cuts-progression/ AllScien 2026-09-14T11:44:13.686888Z Enhertu Phase III win supports first-line expansion in HER2-mutant NSCLC https://allsci.com/news/clinical-trials/zipalertinib-nsclc-combination-halves-progression/ AllScien 2026-09-14T11:32:43.007694Z Cullinan/Taiho's zipalertinib adds six months of PFS in Phase III EGFR ex20ins trial https://allsci.com/news/clinical-trials/tagrisso-survival-preserves-16-point-eight-year/ AllScien 2026-09-14T11:23:43.219503Z Tagrisso shows 16-point eight-year survival advantage in ADAURA https://allsci.com/news/clinical-trials/jnj-1900-nsclc-nanobiotixs-achieves-79-one-year/ AllScien 2026-09-14T10:57:47.808723Z J&J/Nanbiotix’s nanoparticle radioenhancer shows local control signal in recurrent NSCLC https://allsci.com/news/clinical-trials/camizestrant-phase-iii-astrazenecas-etcamah/ AllScien 2026-09-14T09:31:12.132428Z AstraZeneca's Etcamah misses Phase III first-line breast cancer endpoint https://allsci.com/news/clinical-trials/ivonescimab-nsclc-trial-cuts-death-risk-27-versus/ AllScien 2026-09-14T09:19:17.648373Z Ivonescimab cuts death risk 27% versus Keytruda in Phase III NSCLC trial https://allsci.com/news/clinical-trials/tam-peli-sclc-trial-medilinks-cuts-death-risk-54/ AllScien 2026-09-14T09:09:22.481799Z Roche-partnered Tam-Peli cuts death risk 54% in Phase III SCLC trial